Peripheral Nerve Stimulation Therapy for Atrial Fibrillation

NCT ID: NCT05653583

Last Updated: 2023-02-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-31

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a three-arm, single-blinded, randomized, sham-controlled, nonsignificant risk study to assess the feasibility of reducing Atrial Fibrillation burden with peripheral nerve stimulation. The three arms include treatment with a wrist-worn neuromodulation ("wrist device"), treatment with an ear-worn neuromodulation device ("ear device") and sham stimulation with wrist-worn device that does not actually deliver stimulation ("sham device"). ECG patches will be worn on the chest to measure AF episode onset and duration ("ECG Patch"). Additionally, a wrist-worn monitoring device will be used for the measurement of heart rate (HR), heart rate variability (HRV), and other biomarkers ("Cardiac Measurement Device (CMD)"). Finally, subjects will track AF episode onset, duration, and symptom type in an AF diary.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Wrist Device

Twice daily stimulation sessions during the 4-week treatment period

Group Type ACTIVE_COMPARATOR

Wrist Device

Intervention Type DEVICE

peripheral nerve stimulation via wrist-worn device

Ear Device

Twice daily stimulation sessions during the 4-week treatment period

Group Type ACTIVE_COMPARATOR

Ear Device

Intervention Type DEVICE

peripheral nerve stimulation via ear-worn device

Sham Device

Twice daily "stimulation" sessions during the 4-week treatment period

Group Type SHAM_COMPARATOR

Sham Device

Intervention Type DEVICE

Wrist-worn device that does not actually deliver stimulation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Wrist Device

peripheral nerve stimulation via wrist-worn device

Intervention Type DEVICE

Ear Device

peripheral nerve stimulation via ear-worn device

Intervention Type DEVICE

Sham Device

Wrist-worn device that does not actually deliver stimulation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 22 years of age and less than 80 years of age
* Diagnosed with paroxysmal atrial fibrillation, as documented on ECG, trans-telephonic monitoring (TTM), cardiac event monitoring, Holter monitoring, or implantable loop recording (episodes must be longer than 30 seconds to qualify)
* At least one symptomatic atrial fibrillation episodes per month over the last three months
* AF burden of at least 5%, as measured within the past 3 months, with no change in AF treatment since measurement
* Willing to stay on stable medications for the duration of the study
* Able and willing to use their smartphone to download the application associated with the Cardiac Measurement Device
* Competent and willing to provide written, informed consent to participate in the study

Exclusion Criteria

* Prior cardiac ablation, or cardiac ablation planned within 6 weeks of Visit 1
* Cardioversion procedure performed within the last 12 weeks
* Valvular atrial fibrillation by transthoracic echocardiography
* Left atrial anteroposterior diameter greater than 5.5 cm by transthoracic echocardiography
* Prior or planned cardiac transplantation or cardiac surgery
* Cerebral ischemic event (stroke or transient ischemic attack) within the last 6 months
* Myocardial infarction within the last 6 months
* Heart failure (NYHA class III or IV)
* Left ventricular ejection fraction less than 35%
* Recurrent vaso-vagal syncopal episodes
* Unilateral or bilateral vagotomy
* Hemodynamic instability
* Structural heart damage
* Implanted active electrical medical device, such as pacemaker, implantable loop recorders, defibrillator, or deep brain stimulator
* Implanted metal or electrical devices in the head or treated hand
* Not currently on anticoagulants
* History of epilepsy or seizures
* Peripheral neuropathy affecting the upper left extremity
* Pregnancy, anticipated pregnancy, or nursing during the study
* Unable or unwilling to comply fully with study procedures and followup, including atrial fibrillation diary requirements
* Known allergy to any of the device materials that are in contact with prospective subject's skin
* Current participation, or previous participation within the last 30 days, in another interventional clinical trial that may confound the results of this study, unless otherwise approved by the Sponsor
* Subjects unable to communicate with the Investigator and study staff
* Presence of any health condition that should preclude participation in this study, per the Investigator's opinion
Minimum Eligible Age

22 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cala Health, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shahrose Aratia

Role: CONTACT

6506515296

Melissa Nishihama

Role: CONTACT

6506515296

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Colleen Nelson, CNP

Role: primary

Mohamed Elshazly, MD MBEE

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AFIB-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RF Ablation of Atrial Fibrillation
NCT00265629 COMPLETED PHASE1